A Metabolomic Signature Predicts Gout Flare Clinical Outcome Associated with Colchicine Prophylaxis
Arthritis & Rheumatology · 2026
DOI: 10.1002/art.70094 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Arthritis & Rheumatology, 2026. Verfasst von Wenyan Sun und 13 weiteren Autor:innen. Beteiligte Einrichtung: Xiang'an Hospital of Xiamen University, Xiamen, China. Hauptthemen laut MEDLINE: Gout, Colchicine, Gout Suppressants. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Key R&D Program of China, National Natural Science Foundation of China, Key R&D Program of Shandong Province, China.
Abstract (Originalsprache)
Objective
This study investigated that serum metabolomics, prior to ULT initiation, could serve as a biomarker for responsiveness to colchicine prophylaxis in patients with gout commencing treat‐to‐target ULT.
Methods
We studied a multicenter prospective cohort (n=409) initiating treat‐to‐target ULT plus colchicine prophylaxis. Untargeted metabolomics were measured at enrollment. We defined putative colchicine‐response or colchicine non‐response as no‐flare, or > 1 flare, respectively, during 6 months after first colchicine dose. Cox regression and machine learning models defined the metabolomic signatures associated with reported flare activity on colchicine prophylaxis in the cohort.
Results
In our cohort, 36.9% participants experienced at least one flare. Many inflammation‐related metabolites were differentially abundant in the recurrent flare group and correlated with recurrent flare risk. A significant association was found between a four‐metabolite risk score and gout flare activity (adjusted hazard ratio 3.21, 95% CI 2.24‐4.59), independent of the adjusted clinical factors. The machine learning model, which incorporated the top‐ranked metabolites selected by MUVR along with traditional clinical factors, reached an area under the receiver operating characteristic of 0.771 (95% CI 0.713‐0.828) and 0.724 (95% CI 0.611‐0.837) for predicting flare risk in the discovery and validation cohort, respectively.
Conclusions
Metabolomic profile‐defined inflammation status was associated with gout flare outcomes in ULT initiators receiving colchicine prophylaxis. Identification of these novel metabolomic predictive signatures prior to ULT could potentially help optimize clinical decision‐making for flare prophylaxis colchicine dosing and duration in the first 6 months after initiation of treat‐to‐target ULT in gout. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Xiang'an Hospital of Xiamen University, Xiamen, China.
- Shandong Provincial Clinical Research Center for Immune Diseases and Gout, Shandong Provincial Clinical Medical Center for Gout, the Affiliated Hospital of Qingdao University, Qingdao, China.
- Department of Endocrinology and Metabolism, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
- Shanghai Institute of Nutrition and Health, Shanghai, China.
- Institute of Metabolic Diseases, Qingdao University, Qingdao, China.
- University of California San Diego, San Diego, CA, USA.
ORCID-Profile: Wenyan Sun, Lingfang Xu, Haibing Chen, Aichang Ji, Yuwei He, Robert Terkeltaub, Changgui Li
Förderung
- National Key R&D Program of China
- National Natural Science Foundation of China
- Key R&D Program of Shandong Province, China
- Shandong Provincial Natural Science Foundation
Zitieren
APA
Sun, W., Xu, L., Chen, H., Sun, M., Li, Z., Li, R., Ma, L., Zhang, H., Ji, A., He, Y., Wu, N., Yan, L., Terkeltaub, R., & Li, C. (2026). A Metabolomic Signature Predicts Gout Flare Clinical Outcome Associated with Colchicine Prophylaxis. Arthritis & Rheumatology. https://doi.org/10.1002/art.70094
Vancouver
Sun W, Xu L, Chen H, Sun M, Li Z, Li R, et al. A Metabolomic Signature Predicts Gout Flare Clinical Outcome Associated with Colchicine Prophylaxis. Arthritis & Rheumatology. 2026. doi:10.1002/art.70094
BibTeX
@article{Sun2026,
author = {Sun, Wenyan and Xu, Lingfang and Chen, Haibing and Sun, Mingshu and Li, Zhiqiang and Li, Rui and Ma, Lidan and Zhang, Hui and Ji, Aichang and He, Yuwei and Wu, Na and Yan, Le and Terkeltaub, Robert and Li, Changgui},
title = {A Metabolomic Signature Predicts Gout Flare Clinical Outcome Associated with Colchicine Prophylaxis},
journal = {Arthritis & Rheumatology},
year = {2026},
doi = {10.1002/art.70094}
}
EUVIMED